ThinkEquity initiated coverage of Scorpius Holdings with a Buy rating and $5 price target. Scorpius is positioning itself as a key player in the biopharmaceutical industry, offering a range of services including cell- and gene-based therapies and large molecule biologics, the analyst tells investors in a research note. The firm says the company is well positioned to secure U.S. government contracts and biodefense projects.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPX:
- Scorpius Holdings commends passage of the BIOSECURE Act
- Scorpius Holdings selected for RRPV to accelerate countermeasure development
- Scorpius Holdings releases letter to shareholders from CEO
- Scorpius Holdings reports Q2 EPS ($26.98) vs. ($106.67) last year
- Scorpius Holdings Announces Successful Public Offering and Strategic Financing Steps